                         SEQUENCE LISTING / SEQUENZPROTOKOLL

<110>  PMCR GmbH

<120>  HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen

<130>  PMC-0001-P-DE

<140>  DE 10 2019 114 735.2
<141>  2019-06-02

<160>  48

<170>  PatentIn version 3.5

<210>  1
<211>  11
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A antigen peptide

<400>  1
CVGRRNYRFF Y						11

<210>  2
<211>  11
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A antigen peptide

<400>  2
HAVFVQSYY						9

<210>  3
<211>  8
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A antigen peptide

<400>  3
LLDPEDVD						8

<210>  4
<211>  8
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A antigen peptide

<400>  4
HTDIYANY						8

<210>  5
<211>  8
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A antigen peptide

<400>  5
AVFVQSYY						8

<210>  6
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-B antigen peptide

<400>  6
EEEAAAAAAY						10

<210>  7
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-B antigen peptide

<400>  7
MEVLSQEIVR						10

<210>  8
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-B antigen peptide

<400>  8
HMKKMMKDL						9

<210>  9
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-C antigen peptide

<400>  9
SSTALHPCPF						10

<210>  10
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-C antigen peptide

<400>  10
LSYLHVHTA						9

<210>  11
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-C antigen peptide

<400>  11
YSLLSLLHT						9

<210>  12
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-C antigen peptide

<400>  12
CPFTHGSSPM						10

<210>  13
<211>  11
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A neoantigen peptide

<400>  13
YVGRRNYRFF Y						11

<210>  14
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A neoantigen peptide

<400>  14
HVVFVQSYY						9

<210>  15
<211>  8
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A neoantigen peptide

<400>  15
LLDPEDVY						8

<210>  16
<211>  8
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A neoantigen peptide

<400>  16
HMDIYANY						8

<210>  17
<211>  8
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A neoantigen peptide

<400>  17
VVFVQSYY						8

<210>  18
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A neoantigen peptide

<400>  18
DEDEIKWWW						9

<210>  19
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A neoantigen peptide

<400>  19
FVNDKFMPL						9

<210>  20
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-B neoantigen peptide

<400>  20
EEAAAAAAAY						10

<210>  21
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-B neoantigen peptide

<400>  21
MEVLSQEIVW						10

<210>  22
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-B neoantigen peptide

<400>  22
HMKKMMKAL						9

<210>  23
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-C neoantigen peptide

<400>  23
SSTPLHPYPF						10

<210>  24
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-C neoantigen peptide

<400>  24
FSYLHVHTA						9

<210>  25
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-C neoantigen peptide

<400>  25
YSLLSLLHM						9

<210>  26
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-C neoantigen peptide

<400>  26
YPFTHGSSPM						10

<210>  27
<211>  11
<212>  AA
<213>  synthetic construct

<220>
<223>  HLA-A neoantigen peptide

<400>  27
TYLPTNASLS F						11

<210>  28
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  class I neoantigen peptide

<400>  28
DAVIVKLEI						9

<210>  29
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  class I neoantigen peptide

<400>  29
YYLDLSITR						9

<210>  30
<211>  10
<212>  AA
<213>  synthetic construct

<220>
<223>  class I HLA-A neoantigen peptide

<400>  30
ILFGISLREV						10

<210>  31
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  class I HLA-A neoantigen peptide

<400>  31
KVVEFLAML						9

<210>  32
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  class I HLA-A neoantigen peptide

<400>  32
FVNDKFMPL						9

<210>  33
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  class I HLA-A neoantigen peptide

<400>  33
FLLILKRDS						9

<210>  34
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  class I HLA-A neoantigen peptide

<400>  34
RTPLSALCV						9

<210>  35
<211>  9
<212>  AA
<213>  synthetic construct

<220>
<223>  class I HLA-B neoantigen peptide

<400>  35
DEDEIKWWW						9

<210>  36
<211>  17
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  36
EDKKIDFSEF LSLLGDI					17

<210>  37
<211>  17
<212>  AA
<213>  synthetic construct

<220>
<223> class II HLA neoantigen peptide

<400>  37
IHREDEDEIK WWWARLN					17

<210>  38
<211>  17
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  38
STKYSHKSPQ LSVHVTD					17

<210>  39
<211>  30
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  39
KYIQESQALA KRSCGLFQKL GEYYLQNAFL			30

<210>  40
<211>  14
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  40
VDLIVEYEAF PKPE						14

<210>  41
<211>  15
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  41
ATYSGAGYYL DLSIT					15

<210>  42
<211>  17
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  42
HGSSFFLLIL KRDSAFI					17

<210>  43
<211>  17
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  43
YSMKCKNVVP LNDLLLE					17

<210>  44
<211>  15
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  44
PLQIILMPQV QPGLP					15

<210>  45
<211>  15
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  45
LLHTEYSLLS LLHMQ					15

<210>  46
<211>  15
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  46
NYLAEEITVD VRDEF					15

<210>  47
<211>  15
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  47
REIDVLEREL NVLIF					15

<210>  48
<211>  15
<212>  AA
<213>  synthetic construct

<220>
<223>  class II HLA neoantigen peptide

<400>  48
PSNYQPHQAC RITFL					15